The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
T-cell engagers and TCRs: clinical progress, antigen challenges, and tumor microenvironment insights
In this roundtable discussion, Michael Gormally, MD, Phd, Memorial Sloan Kettering Cancer Center, New York, NY, and Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, explore the evolving landscape of T-cell receptor (TCR) therapies and T-cell engagers in solid tumors. Dr Gormally presents on immunologic targeting of undruggable TP53 hotspot mutations through TCR gene therapy, highlighting the potential to address previously inaccessible oncogenic drivers. Dr Luke discusses targeting PRAME with TCR T cells, initially in melanoma and expanding to other cancers, emphasizing the versatility of this approach. Their discussion underscores the promise of TCR-based therapies in overcoming challenges posed by intracellular antigens and the tumor microenvironment. This discussion took place at the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025 held in Miami, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved
